Summary Trabectedin is a novel anticancer drug active against soft tissue sarcomas. Trabectedin is a substrate for P-glycoprotein (P-gp), which is encoded by mdr1a/1b in rodents. Plasma and tissue distribution, and excretion of [ 14 C]-trabectedin were evaluated in wild-type and mdr1a/1b (−/−) mice. In parallel, we investigated the toxicity profile of trabectedin by serial measurements of blood liver enzymes and general pathology. [
Introduction
Trabectedin (ET-743, Yondelis™) belongs to the ecteinascidins, which are tetrahydro-isoquinoline compounds isolated from the marine tunicate Ecteinascidia turbinata [1] [2] [3] . Intravenous trabectedin (ET-743, Yondelis™, Fig. 1 ) is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcomas (STS) after failure of anthracyclines and ifosfamide, or in patients who are unsuited to receive those agents [4] . Trabectedin has received orphan drug status for treating STS and for treating recurrent ovarian cancer in the United States and Europe [5] .
Structurally, trabectedin is composed of three tetrahydroisoquinoline subunits and a central carbinolamine moiety, which enables it to bind covalently to DNA, see Fig. 1 [6] .
Trabectedin displays sequence-specific binding to the minor groove of duplex DNA, bending the double helix towards the major groove and affecting the transcription of genes, including the MDR1 gene (ABCB1) that codes for P-gp [7] [8] [9] [10] [11] .
Trabectedin is a very potent compound. The approved dose is 1.5 mg/m 2 every 3 weeks, resulting in total doses of approximately 3 mg by i.v. infusion over 24 h. These doses, in combination with a very large volume of distribution (V ss , 1,000 to 4,000 L [12] ), result in plasma concentrations in the picogram to low nanogram per mL range. Trabectedin also displayed a large volume of distribution (Vss, 15-20 L/kg [13] ) in laboratory animals. The excretory fate of trabectedin is largely unknown. In rats, less than 0.5% of the dose administered was recovered in bile as trabectedin, suggesting an important role for metabolism in the elimination of trabectedin [13] . Urinary excretion of trabectedin in man is reported to be less than 1% of the dose administered, and biliary excretion of unchanged trabectedin is also very low [14] [15] [16] , indicating that metabolism is the major route of elimination. However, the pathways involved in the metabolism of trabectedin are largely unknown. Isolation of metabolites from biological matrices and further structural elucidation is very difficult because of their very low concentrations [15] . Metabolic and degradation products were identified after incubation with human serum, liver microsomes, and UDP-glucuronyl transferase [14] , and in vitro studies with liver microsomes suggest that trabectedin is mainly metabolized by CYP3A4 and to a minor extent by CYPs 2C9, 2C19, 2D6 and 2E1 [13, 17] .
Although clinically, dose-limiting toxicities are primarily related to the effects of trabectedin on bone marrow, hepatotoxicity, as manifested by transient elevation of serum liver enzymes, is frequently observed with all administration schedules [12] . The biochemical basis of the liver toxicity is unknown. Intriguingly, the magnitude of the elevation of liver enzymes diminishes after repeated cycles. A possible explanation is that there are changes in the expression of enzymes or transporters involved in elimination of trabectedin and/or its metabolites.
Recent in vitro investigations in our institute have shown that trabectedin is a P-gp substrate; however, P-gp only confers resistance to trabectedin when expressed at high levels [18] , and there are reports suggesting resistance to trabectedin by non-P-gp related pathways [19, 20] , including a deficiency in transcription-coupled nucleotideexcision repair [21] .
Besides the association of P-gp expression with reduced cytotoxicity in tumor cells and with therapeutic failure, P-gp can also play an important role in the plasma pharmacokinetics and tissue distribution of its substrates [22] [23] [24] [25] [26] [27] . P-gp is expressed at high levels at specific organbarriers like the blood-brain barrier, the blood-testis barrier, and the blood-placenta barrier and limits the entry of substrate drugs into these sanctuary sites. Moreover, P-gp is expressed in organs like the gut, liver and kidneys where it is involved in the excretion of drugs from the body [27] . Therefore, we designed a study using P-gp-deficient (mdr1a/1b(−/−)) mice [23] to explore the role of P-gp in the disposition and toxicity of trabectedin in vivo.
Materials and methods

Drugs and chemicals [
14 C]trabectedin, provided by PharmaMar (Madrid, Spain), originated from Biodynamics Radiochemicals (Billingham, UK) and was purified by HPLC to >97.5% radiochemical purity [16] . Non-labelled trabectedin was provided as lyophilized product for injection by PharmaMar. [D 6 ] trabectedin was provided by PharmaMar (Madrid, Spain).
Bovine serum albumin fraction V (BSA) was obtained from Roche Diagnostics GmBH (Mannheim, Germany). Water was purified by the Milli-Q Plus® system (Millipore, Milford, USA). All other chemicals were of analytical grade.
Animals
FVB wild-type (WT) and P-gp knock-out type (mdr1ab(−/−)) mice, 9-14 weeks of age, were housed and handled in accordance with Dutch national law. The animals had access to food (Hope Farms B.V., Woerden, The Netherlands) and acidified water ad libitum. All experiments were approved by the local ethics committee for animal experiments.
Maximum tolerable dose
To establish the single administration maximum tolerable dose (MTD) of trabectedin, groups (6 mice each) of male and female wild-type and mdr1a/1b(−/−) mice were dosed at 50, 100, 150, 200, 250 and 300 μg/kg and monitored for 14 days. Mice were euthanized upon loss of 20% of the initial body weight, and counted as a toxic death. The MTD was defined as the highest dose level where none of 6 mice died as a consequence of the drug, loss of body weight of individual mice did not exceed 20%, or the average loss of body weight in the group did not exceed 15%.
Hepatotoxicity
To investigate the role of P-gp in the hepatotoxicity of trabectedin, male and female wild-type and mdr1a/1b(−/−) mice (9 mice per group) were dosed at their respective MTD. Female mdr1a/1b(−/−) mice were also dosed at 150 μg/kg, which is below their MTD, to allow comparison with male mdr1a/1b(−/−) mice. The liver function parameters alanine aminotransferase (ALAT/SGPT), aspartate aminotransferase (ASAT/SGOT), total bilirubin and alkaline phosphatase (AP) were monitored daily for up to 7 days by serial blood sampling. Jaundice was defined as macroscopic observation of yellow-colored skin of the mice. Blood samples were collected in heparinized glass capillaries and transferred into polypropylene vials followed by centrifugation (10 min, 6,000×g). A 20-25 μl aliquot of plasma was diluted fourfold with saline and assayed the same day by a Hitachi 917 Analyzer (Roche Diagnostics, Indianapolis, IN, USA) using standard protocols.
Pathology
Autopsies were performed at day 4 or day 14 after trabectedin administration at the respective MTD (N=2 per group). Expert pathology reports were prepared by a trained animal Pathologist of the Netherlands Cancer Institute. The tissues dissected for analysis of radioactivity included: plasma (from blood from the heart), brains, muscle (from the back), abdominal fat, colon, cecum, small intestine, stomach (all emptied), liver, gallbladder, kidneys, lungs, spleen, heart, thymus, abdominal lymph nodes, testes, epidydimus, adrenal glands, bone, skin and pancreas.
Tissues that were only analyzed for total radioactivity content were weighed and dissolved in 1 mL Solvable tissue solubilizer (Packard, Groningen, The Netherlands), followed by quantitation of radioactivity. Other tissues were analyzed for both total radioactivity and parent drug, and were weighed and homogenized in 2 mL of a 4% bovine serum albumin solution in water. Brains and liver were homogenised in 3 and 5 mL, respectively, and plasma was diluted with at least 1 volume of 4% BSA. A 200-μL aliquot of each homogenate was analyzed for radioactivity by liquid scintillation counting after addition of 4 mL of Ultima Gold scintillation fluid (Packard, Groningen, The Netherlands). Counting was performed using a Tricarb 2300 TR Liquid Scintillation Analyzer (Packard, Meriden, CT, USA) with automating quench correction.
Tissues homogenized with 4% BSA were assayed for trabectedin concentration using an adapted validated LC-MS/MS method [28] . After addition of [D 6 ]-trabectedin as internal standard, 500 μL aliquots of homogenate were extracted twice with 5 mL of diethyl ether. Pooled organic layers were evaporated to dryness under a gentle stream of nitrogen, and stored at −20°C until analysis. Reconstitution was performed by vortexing and sonication (5 min 
Metabolism
The metabolism of trabectedin was investigated by gallbladder cannulation [29] of a single WT mouse (male, 13 weeks). Bile was collected for 1.5 h following intravenous administration of 200 μg [ 14 C]-trabectedin/kg body weight. A 20-μL aliquot of bile was diluted 20-fold in methanol:phosphate buffered saline (1:10, v/v) followed by extraction with 4 mL of diethylether. After shaking (5 min), the aqueous layer was frozen using ethanol and dry-ice. The organic layer was separated and evaporated to dryness under a gentle stream of nitrogen followed by reconstitution in 400 μL of methanol:phosphate buffered saline (1:10, v/v). The aqueous phase was diluted (1:1, v/v) with methanol: phosphate buffered saline (1:10, v/v). Each solution was injected onto a Symmetry C18 column (150×4.6 mm, 3.5 μm, Waters, Milford, USA). A binary gradient was applied at 1 mL/min using two Spectroflow SF400 pumps (Kratos, Ambacht, The Netherlands). Mobile phase A consisted of 10 mM ammonium acetate + 0.04% formic acid (pH=4.0), and mobile phase B consisted of methanol:10 mM ammonium acetate + 0.04% formic acid (30:70, v/v). An 18-min linear gradient from 43% to 100% B was followed by 100% B until 23 min. Eluate fractions were collected every 18 s. After addition of 3 mL scintillation fluid, radioactivity was determined off-line by liquid scintillation counting.
Data analysis
AUC values were calculated in Excel (Microsoft Corporation, Redmond, WA) based on the linear trapezoidal rule. Statistical analysis of AUC values consisted of calculation of the mdr1a/ 1b(−/−) to wild-type AUC ratio with the associated standard error (SE). After log-transformation, these ratios were subjected to a two-sided Students t-test, under the nullhypothesis of log(AUC-ratio)=0.
Excretion of radioactivity in urine, feces, and the total excretion of [ 14 C]-trabectedin in mdr1a/1b(−/−) and wild-type male mice was compared with a two-sided Students t-test.
A value of p<0.05 was considered statistically significant.
Results
Maximum tolerable dose
The MTD of trabectedin was 250 μg/kg in both male and female wild-type mice. However, we observed a sex-based difference in the mdr1a/1b(−/−) mice. Male mice were more sensitive, as the MTD was 150 μg/kg whereas the MTD in females was 250 μg/kg, see Table 1 . Mice receiving trabectedin at dose levels exceeding the MTD suffered from general malaise (manifested by inactivity and pilo-erection) which most likely caused insufficient food and fluid intake. Animals were euthanized when their body weight loss exceeded 20%. Other macroscopic signs of toxicity were mild alopecia behind the ears of female mdr1a/1b(−/−) mice, and occasional jaundice, particularly in male mdr1a/1b(−/−) mice.
Hepatotoxicity
Elevation of liver enzymes is common after administration of trabectedin to cancer patients. The biochemical basis of this hepatotoxicity is unknown. In this study, we have explored the role of P-gp in the hepatotoxicity of trabectedin in mice by serial determination of liver enzymes in plasma. None of the mice in these series experienced more than 20% loss of body weight during the observation period, and the toxicity profile was similar to that in the mice used for the determination of the MTD. Only male and female mdr1a/1b (−/−) mice displayed mild jaundice. Levels of plasma ALAT, ASAT, bilirubin, and AP are presented in Fig. 2 . Given the large inter-animal variability in plasma liver enzyme elevations, the number of animals used did not allow rigorous statistical analysis between all groups. In general, ALAT, ASAT and bilirubin levels increased at 24 h after dosing, reached a maximum within approximately 3 days, and returned to baseline levels after approximately 1 week. Plasma levels of AP started to increase after 48 h, and reached a maximum at 4 days after dosing. On an opportunistic basis we re-dosed a cohort of male wild-type and female mdr1a/1b(−/−) mice with 250 μg/kg trabectedin, 6 weeks after the first dose. This resulted in a slightly increased hepatotoxicity pattern in the female mdr1a/1b(−/−) mice, whereas hepatotoxicity was decreased in the male wild-type mice.
Pathology
Bone marrow was depleted in all the mice euthanized 4 days after dosing, but had recovered by day 14. Small 
a This death was not considered drug-related as it showed an atypically sharp decline in body-weight starting the day of administration b This death was excluded as the mouse suffered from a tailinflammation at the site of injection focal degeneration of hepatic tissue was observed in all male and female mdr1a/1b(−/−) mice at both the day 4 and 14 time points, which in approximately half the cases was accompanied by signs of cholangitis and bile duct proliferation. Because this was a different cohort of mice than the mice used in the hepatotoxicity study, the presence of cholangitis and bile duct proliferation could not be correlated with biochemical parameters such as ALAT, ASAT, AP or bilirubin. In female mdr1a/1b(−/−) mice only, degeneration of the kidney tubules and hypotrophic degeneration of the heart muscle were observed. In all of the female mdr1a/1b(−/−) mice, the incisors showed degeneration of the dentine. Degeneration of the intervertebral discs was observed across all groups, apparently without a specific pattern.
Tissue disposition P-gp can have a major impact on the disposition of substrate drugs such as trabectedin. We therefore investigated the effect of P-gp on [ 14 C]trabectedin disposition. Results are shown in Fig. 3 and Table 1 .
The total plasma radioactivity versus time profile after administration of [ 14 C]trabectedin was similar in wild-type and mdr1a/1b(−/−) male mice. LC-MS/MS quantification of trabectedin in plasma revealed that trabectedin is rapidly metabolised. At 20 min and 3 h after administration, only about 40 and 10% respectively of the radioactivity in plasma represented unchanged trabectedin. The plasma concentration versus time profile of unchanged trabectedin in mdr1a/1b(−/−) and wild-type mice were similar during the first hours after drug administration ( Table 2) . The tissue-to-plasma ratios showed that radioactivity is extensively distributed from plasma to tissues, in both wildtype and mdr1a/1b(−/−) mice. Tissue-to-plasma ratios of [ 14 C]trabectedin were always larger than unity, except for the brain in wild-type mice. In most tissues, radioactivity was initially eliminated rapidly, followed by a slower terminal elimination phase. Exceptions were the spleen, thymus, lymph nodes, testis of both genotypes and the brain of mdr1a/1b(−/−) mice, which displayed prolonged retention of radioactivity.
The effect of the absence of P-gp on the tissue distribution is most pronounced in the mdr1a/1b(−/−) brain (13-fold increase) and testis (twofold increase) relative to the wild-type controls. Differences were also observed in the small intestines, kidneys, and heart, all organs known to express P-gp [22] [23] [24] [25] [26] [27] . LC-MS/MS quantitation of trabectedin in tissues showed that only a fraction of radioactivity was accounted for by unchanged compound. In brain at 7 min after dosing, trabectedin accounted for approximately 25% and 20% of radioactivity in mdr1a/1b(−/−) and wild-type mice, respectively. Thereafter, trabectedin concentrations in wild-type brain fell below the LLQ while trabectedin concentrations were maintained at a higher level in mdr1a/1b(−/−) brain. At 20 min after administration, trabectedin accounts for approximately 20% and 10% of testis radioactivity in mdr1a/1b(−/−) and wild-type mice, respectively. The trabectedin ratio in mdr1a/1b(−/−) to wild-type testis at that time point was approximately 4.5. Liver concentrations of trabectedin represented only 1.5% or less of radioactivity at 8 h after administration and were similar in mdr1a/1b(−/−) and wild-type mice. These results indicate the importance of P-gp in trabectedin disposition. Time (h) 
Excretion and metabolism
We determined the effect of P-gp on the excretion of [ 14 C] trabectedin in wild-type and mdr1a/1b(−/−) mice (Fig. 4) . Feces was the predominant excretory pathway in both wildtype (70.6±13.9%) and mdr1a/1b(−/−) mice (75.4±2.3%). The contribution of urinary excretion (2.3±1.3% and 2.2± 0.9%, respectively) to total recovery (72.9±13.1% and 77.6± 2.5%, respectively) was minimal.
No significant differences were observed in urinary, fecal or total excretion between the wild-type and mdr1a/1b(−/−) mice (P≥0.50 for fecal, urinary, and total excretion at all time points). Given the finding that only a small fraction of radioactivity in plasma and tissues was unchanged drug, we anticipated that unchanged trabectedin was only a minor component of the excreted radioactivity. In that intraintestinal degradation of trabectedin may occur, we fitted a single, male, wild-type mouse with a cannulated bile duct to investigate the composition of the excreted radioactivity in the bile (0-90 min sample). The resulting radiochromatogram is shown in Fig. 5 with trabectedin eluting at about 11.4 min, and representing only about 2.5% of the total radioactivity of the bile sample. The total bile sample collected over 1.5 h contained approximately 1.6% of the radioactive dose administered. Because the concentration of the compounds in the sample was very low and the UV chromatogram of the fractionation (not shown) indicated the presence of large amounts of matrix-derived interferences, further structure analysis of fractions (e.g. by means of mass spectrometry) was not feasible. Trabectedin appeared to be extensively metabolised to a large number of more polar as well as less polar metabolites, and was itself only a minor contributor to biliary excretion, even within the first 1.5 h after dosing. 
Discussion
This study shows that the in vivo disposition of trabectedin is affected by P-gp. As expected, P-gp decreases the penetration of trabectedin into the brain and the testis as they are protected by a specific blood-organ barrier expressing P-gp. We also observed a decreased penetration of the heart, confirming earlier reports on doxorubicin disposition that suggest a role for P-gp in decreasing cardiac exposure to xenobiotics [24] . However, the effect of P-gp on trabectedin disposition in the heart is smaller than in the brain or testis because this organ is not shielded by a blood-organ barrier, although the heart endothelium does express P-gp. In contrast to reports on other P-gp substrate drugs [30] [31] [32] , we did not observe a decreased clearance of unchanged trabectedin in mdr1a/1b(−/−) mice. The reason that the clearance is not reduced in mdr1a/1b(−/−) mice may be that metabolic clearance is the most important route of elimination of trabectedin. As our data show, liver concentrations of total radioactivity and unchanged trabectedin are high and unaffected by P-gp status. Other P-gp substrates that do show a decreased clearance in mdr1a/1b (−/−) mice, are commonly excreted unchanged in substantial amounts by the liver or gut and a major part of this excretion is mediated by P-gp [29, 33] . As only a minor fraction of the radioactivity that was excreted into the bile of a wild-type mice represented unchanged trabectedin, the absence of P-gp in mdr1a/1b(−/−) mice was probably unable to significantly decrease the trabectedin clearance.
In the disposition study, the male mdr1a/1b(−/−) and wild-type mice received trabectedin at the same dose of 150 μg/kg and this resulted in similar plasma exposure. This dose, however, was not equitoxic to both strains as it was well below the MTD of wild-type mice but at the MTD of the mdr1a/1b(−/−) mice. Therefore, the difference in the MTD between male mdr1a/1b(−/−) and male wild-type mice cannot satisfactorily be explained by a difference in plasma exposure to trabectedin. Similarly, while there was no difference in the trabectedin accumulation in the liver between the two strains, we did observe a more severe hepatotoxicity in the mdr1a/1b(−/−) mice. The absence of a clear relationship between plasma and liver exposure to trabectedin and toxic effects might suggest that metabolites of trabectedin are involved in the toxicity, and that they may be P-gp substrates. The bile experiment showed that the liver excreted a large number of radioactive trabectedin metabolites, in agreement with the human metabolic profile of trabectedin [15, 16] . Besides a range of more polar compounds, we also observed several hydrophobic metabolites in bile, which is different from the reports in humans. Due to the low quantities of these metabolites, further structural characterization (e.g. by mass spectrometry) was not feasible. Earlier in vitro studies have shown that human metabolism of trabectedin is mediated by CYP450 enzymes with a major role for 3A4 and minor contributions of 2C9, 2C19, 2D6, and 2E1 [13, 17] . The expression of CYP450 enzymes (including CYP3A2, the rodent counterpart of human CYP3A4) in rats and mice is known to be sexdependent [34, 35] . Moreover, there are reports of changes in CYP450 expression in mdr1a/1b(−/−) relative to wildtype mice [36] . In addition, expression of other transporters may also be modified in mdr1a/1b(−/−) as compared to wild-type mice. A recent study suggested a role for the multidrug resistance related proteins (Mrp2, Mrp3 and Mrp4 in the hepatotoxicity of trabectedin [37] .
Consequently, gender and strain differences in CYP450 enzymes expression resulting in variations in the metabolic fate of trabectedin may partly explain the observed differences in toxicity at similar plasma exposures. In future studies, it may be advisable to determine the expression levels of CYP enzymes and other known drug transporters.
Our experiments confirm earlier reports that hepatotoxicity of trabectedin in mice is non-cumulative and reversible [38] . This is in parallel with humans [39] [40] [41] but opposed to rats where plasma ASAT, AP and bile acid levels remained elevated for several months after dosing [12, 42, 43] . Therefore, the mouse appears to be a better species than rats as a model of trabectedin-induced hepatotoxicity trabectedin. However, metabolic profiles highly differ between species, with major differences between mice, dogs and rats, and greater similarity between human and primate metabolism, and therefore the best model was reported to be a monkey model [44, 45] . The decreased hepatotoxic response of wild-type mice after a repeated injection of trabectedin may be due to up-regulation of detoxifying pathways. Interestingly, we did not observe a decreased hepatotoxicity in mdr1a/1b(−/−) mice, which may suggest the involvement of P-gp. Interestingly, up-regulation of canalicular P-gp has been observed in rats after trabectedin administration [42] , even if the expression of other pumps and enzymes may have been altered. It is unlikely that upregulation of P-gp results in a markedly enhanced hepatobiliary excretion of trabectedin, but it may aid in the elimination of other, possibly toxic, metabolites of trabectedin. Increased efflux of toxic metabolites could explain reduced toxicity in the wild-type mice and slightly increased toxicity in mdr1a/1b(−/−) mice after repeated dosing.
The degree of hepatotoxicity was also determined by gender. However, the hepatotoxicity is not a dose-limiting event per se. While both strains were dosed at 250 μg/kg (the MTD in both strains), female wild-type mice experienced (almost) no hepatotoxicity, whereas we observed serious hepatoxicity in female mdr1a/1b(−/−) mice. Apparently, there are other trabectedin toxicities resulting in a decreased well-being, and ultimately death. Pathology of the animals revealed other toxicities, however, none of these were clearly dose limiting either. The bone marrow depletion observed 4 days after administration, which had recovered at day 14, is in keeping with the dose limiting toxicities observed in humans (thrombocytopenia, neutropenia, pancytopenia) [12] . Pathological examination of mdr1a/1b(−/−) and wild-type mice revealed some striking differences in toxicity at the organ-level. The observations in the liver are relatively mild and in line with the reversible nature of the hepatotoxicity. The degeneration of the kidney tubules and the degenerative cardiomyopathy in female mdr1a/1b(−/−) mice is suggestive of a protective role for P-gp. However, the involvement of other enzymes, whose expression may be affected by the absence of P-gp, cannot be ruled out. The absence of similar pathologic effects in male mdr1a/1b(−/−) mice may be due to the lower dose administered (MTD 150 μg/kg relative to 250 μg/kg in females).
In conclusion, P-gp is important for the in vivo disposition of trabectedin as its expression decreased the distribution into the testis and the brain. However, P-gp does not significantly influence the clearance of trabectedin. Consequently, differences in toxicities between wild-type and mdr1a/1b(−/−) mice could not adequately be explained by differences in plasma exposure of unchanged drug. This suggests that either tissue-specific distribution of trabectedin, or metabolites of trabectedin determine its toxicity profile.
